Trials / Completed
CompletedNCT01055535
Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion
An Open Label, Single Centre Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- ThromboGenics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of Microplasmin administered as an intravitreal injection, in subjects with focal vitreomacular adhesion. Ultimately, it is believed that intravitreal microplasmin may offer physicians a safe agent for pharmacologic vitreolysis and induction of Posterior Vitreous Detachment (PVD) without the need for vitrectomy. This clinical study is justified because the study sponsor believes the potential benefits outweigh the potential risks, as outlined below.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Microplasmin | 125 µg intravitreal injection |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2011-04-01
- Completion
- 2011-04-01
- First posted
- 2010-01-25
- Last updated
- 2014-04-07
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT01055535. Inclusion in this directory is not an endorsement.